Preview

Медицинский Совет

Расширенный поиск

ИНГИБИТОРЫ ДИПЕПТИДИЛПЕПТИДАЗЫ-4: ВЗГЛЯД КЛИНИЧЕСКОГО ФАРМАКОЛОГА

https://doi.org/10.21518/2079-701X-2016-19-114-121

Полный текст:

Аннотация

Более глубокое понимание патогенеза сахарного диабета 2-го типа, включая постпрандиальный контроль гомеостаза глюкозы, привело к появлению новых стратегий лечения, направленных на преодоление дисфункции панкреатических островков и, в частности, воздействующих на инкретиновые гормоны кишечника. Ингибиторы дипептидилпептидазы-4 (ДПП-4) – один из первых классов пероральных препаратов для лечения сахарного диабета, разработанных целенаправленно как антигипергликемические лекарственные средства. Ингибирование разрушения инкретинового гормона – глюкагоноподобного пептида-1 – оказывает положительное влияние на гомеостаз глюкозы (включающий как потенцирование индуцированного глюкозой повышения уровня инсулина, так и подавление секреции глюкагона). Низкий риск гипогликемий, отсутствие выраженных побочных эффектов и влияния на массу тела выгодно отличают класс ингибиторов ДПП-4 от других групп пероральных сахароснижающих средств.

Об авторе

Н. Б. ЛАЗАРЕВА
Первый Московский медицинский университет им. И.М. Сеченова
Россия
д.м.н., профессор


Список литературы

1. International Diabetes Federation. IDF Diabetes, 7 ed. Brussels, Belgium: International Diabetes Federation, 2015. http://www.diabetesatlas.org.

2. Roglic G. World Diabetes Congress 2015: The Global Health Challenges Stream // Diabetes research and clinical practice. 2015. Т. 108. №. 2. С. 367-368.

3. Inzucchi SE, Bergenstal RM, Buse JB, et al; American Diabetes Asso ciation (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379.

4. Deacon C. F., Lebovitz H. E. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas Diabetes, Obesity and Metabolism 18: 333–347, 2016.

5. White WB, Cannon CP, Heller SR et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med, 2013; 369:1327–1335.

6. Green JB, Bethel MA, Armstrong PW et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med, 2015; 373: 232–242.

7. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes, 1998; 47: 1663–1670.

8. Deacon CF, Holst JJ. Pharmacology of GLP-1-based therapies.Review of Endocrinology 2008 (January): 17–22.

9. Ahren B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptinin humans. Diabetes Obes Metab 2011; 13: 775–783.

10. Nabeno M, Akahoshi F, Kishida H et al. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem Biophys Res Commun 2013; 434: 191–196.

11. Tatosian DA, Guo Y, Schaeffer AK et al. Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. Diabetes Ther 2013; 4:431–442.

12. McKeage K. Trelagliptin: first global approval. Drugs 2015; 75: 1161–1164.

13. Furuta S, Smart C, Hackett A, Benning R, Warrington S. Pharmacokinetics and metabolism of [14C] anagliptin, a novel dipeptidyl peptidase- 4 inhibitor, in humans. Xenobiotica 2013; 43: 432–442.

14. American Diabetes Association. Standards of medical care in diabetes 2014. Diabetes Care 2014; 37(Suppl. 1): S14–S80.

15. Davis TM. Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment. Diabetes Obes Metab 2014;16: 891–899.

16. Xu S, Kauh A, Tatosian D et al. Absorption, metabolism, and excretion of [14C]omarigliptin, a once-weekly DPP-4 inhibitor, in humans. Poster presented at 74th American Diabetes Association Scientific Sessions, San Francisco, 2014; Poster 1080-P. Available from the ADA ePoster archives via URL: https://ada.scientificposters.com/eps- SearchADA.cfm. Accessed 27 October 2015.

17. European Medicines Agency. Alogliptin; Summary of product characteristics.Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002182/ WC500152271.pdf. Accessed 30 July 2015.

18. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011; 13: 7–18.

19. European Medicines Agency.Linagliptin; Summary of product characteristics.Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002110/WC500115745.pdf. Accessed 30 July 2015.

20. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011; 13: 7–18.

21. European Medicines Agency.Saxagliptin; Summary of product characteristics. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_ Information/human/001039/ WC500044316.pdf. Accessed 30 July 2015.

22. European Medicines Agency.Sitagliptin; Summary of product characteristics. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000722/ WC500039054.pdf. Accessed 30 July 2015.

23. European Medicines Agency.Vildagliptin; Summary of product characteristics.Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000771/ WC500020327.pdf. Accessed 30 July 2015.

24. Deacon CF, Holst JJ. Pharmacology of GLP-1-based therapies.Review of Endocrinology 2008(January): 17–22.

25. Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetesmellitus. Diabetes Metab Res Rev 2010; 26: 540–549.

26. American Diabetes Association. Position Statement. Standards of medical care in diabetes – 2013. Diabetes Care. 2013;36 (1):S11–S66.

27. Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist , Gause-Nilsson I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2010; 26(7): 540–549.

28. Marfella R, Barbieri M, Grella R, Rizzo MR, Nicoletti GF, Paolisso G. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complications 2010; 24:79–83.

29. Guerci B, Monnier L, Serusclat P et al. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study. Diabetes Metab 2012; 38: 359–366.

30. Недогода С.В., Барыкина И.Н., Саласюк А.С., Смирнова В.О. Фармакоэкономический анализ использования алоглиптина в лечении сахарного диабета 2 типа. Качественная клиническая практика. 4 2015; 43-52.

31. Esposito K. et al. A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients. // BMJ open. 2015. Т5. 2. С. e005892.

32. Шестакова Е.А., Галстян Г.Р. Ингибиторы дипептидилпептидазы-4: сравнительный анализ представителей группы. Проблемы эндокринологии. 2012, 1. 61-66.

33. Capuano A, Sportiello L, Maiorino M et al. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin. Drug Design, Development and Therapy 2013:7 989– 1001.

34. Goosen K, Graber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab 2012; 14:1061–1072.

35. Gallwitz B. Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes. Diabetes Metab Syndr Obes. 2013;6:1–9.

36. Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibi tors for the treatment of type 2 diabetes mellitus. Pharmacotherapy. 2010; 30(5):463–484.

37. Mikhail N. Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes. Curr Drug Saf. 2011;6(5):304–309.

38. White WB, Cannon CP, Heller SR et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369:1327–1335.

39. Green JB, Bethel MA, Armstrong PW et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes.N Engl J Med 2015; 373: 232–242.

40. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and nadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care. 2008;31(12):2315–2317.

41. White WB, Bakris GL, Bergenstal RM, et al. EXamination of CAr diovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011;162(4):620–626.e1

42. Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 008 Group. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo- controlled study. Int J Clin Pract. 2009; 63(1):46–55.

43. Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 009 Group. Efficacy and safety of the dipeptidyl pepti dase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, doubleblind, placebo-controlled study. Curr Med Res Opin. 2009; 25(10): 2361–2371.

44. Pratley RE, KipnesMS, Fleck PR, Wilson C, Mekki Q; Alogliptin Study 007 Group.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab. 2009; 11(2):167– 176.

45. Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab. 2009;11(12):1145–1152.

46. Pratley RE, McCall T, Fleck PR, Wilson CA, Mekki Q. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc. 2009; 57(11):2011–2019.

47. Andukuri R, Drincic A, Rendell M. Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabetes Metab Syndr Obes. 2009; 2:117–126.


Для цитирования:


ЛАЗАРЕВА Н.Б. ИНГИБИТОРЫ ДИПЕПТИДИЛПЕПТИДАЗЫ-4: ВЗГЛЯД КЛИНИЧЕСКОГО ФАРМАКОЛОГА. Медицинский Совет. 2016;(19):114-121. https://doi.org/10.21518/2079-701X-2016-19-114-121

For citation:


LAZAREVA N.B. DIPEPTIDYL DIPEPTIDASE-4: VIEW OF THE CLINICAL PHARMACOLOGIST. Medical Council. 2016;(19):114-121. (In Russ.) https://doi.org/10.21518/2079-701X-2016-19-114-121

Просмотров: 202


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)